Few differences of clinical importance for outcomes related to effectiveness were found in a new review of first-generation and second-generation antipsychotic medications for adults with schizophrenia, schizophrenia-related psychoses, or bipolar disorder. The review also found that outcomes such as death and quality of life were rarely assessed, and that data comparing side effects were sparse. Inconsistency in treatment comparisons, outcomes, outcome measurements, and patient populations across studies made drawing firm conclusions difficult; however, the research review provides extensive details of characteristics and methodological features of the studies that may help inform individual treatment decisions.
–U.S. Dept. of Health and Human Services